COMMUNIQUÉS West-GlobeNewswire

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
10/09/2025
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF [...]
Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference
10/09/2025
London – 10 September 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announced that members of its management team will participate in the [...]
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
10/09/2025
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with [...]
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
10/09/2025
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Les données publiées dans The New England Journal of Medicine démontrent que l’association de RYBREVANT®▼ (amivantamab) et de LAZCLUZE®▼ (lazertinib) serait susceptible de redéfinir les perspectives de survie dans le traitement de première
10/09/2025
Ce schéma thérapeutique combiné sans chimiothérapie pourrait ouvrir une nouvelle ère dans le traitement de première intention, avec une survie globale médiane prévue supérieure à quatre ans, dépassant ainsi de plus d’un [...]
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
10/09/2025
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to [...]
IPG Health expands Influencer ID marketing expertise into Europe
10/09/2025
Strategic rollout will scale US success into key European markets, strengthening the network’s leadership of social media strategy in the health/pharma sector LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- IPG Health is [...]
Dogecoin Cash, Inc. Subsidiary PrestoDoctor Now Accepts Cryptocurrency Payments, Including Dogecoin
10/09/2025
MESQUITE, NV, Sept. 10, 2025 (GLOBE NEWSWIRE) -- September 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation,announced that its wholly owned subsidiary, [...]
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
10/09/2025
Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to advance pivotal [...]
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025
10/09/2025
Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Investor Science and [...]
Novo Nordisk to streamline operations and reinvest for growth
10/09/2025
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients Intention to reduce ~9,000 roles globally with the [...]
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
10/09/2025
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 [...]
Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2
10/09/2025
Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2 Approbation basée sur l’étude TN-10, qui démontre la [...]
Pharming Group promoted to the Euronext AMX® index
10/09/2025
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® ( [...]
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
10/09/2025
BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, [...]
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
10/09/2025
NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]
Rapport Announces Pricing of Public Offering of Common Stock
10/09/2025
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
10/09/2025
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed [...]
Significant Breakthrough! eefit Far Infrared Technology Improves Two Major Symptoms of Alzheimer’s Disease, Bringing New Hope to Brain Health Protection
09/09/2025
Hong Kong, Sept. 09, 2025 (GLOBE NEWSWIRE) -- With Hong Kong’s aging population, Alzheimer’s disease has become a major public health challenge. The Hong Kong Council of Social Service projects that by 2036, the number [...]

Pages